06.03.2023 - Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial ...